COEP
Price:
$0.142
Market Cap:
$5.84M
Coeptis Therapeutics, Inc., a biopharmaceutical company, develops and commercializes generic and branded pharmaceutical products and cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a Vy-Gen drug product for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; and CD38-Diagnostic, an in vitro screening tool to provide the ability to pre-determine which cancer patients are most likely to benefit from targeted anti-CD38 monoclonal antibodies therapies. The company has collaboration with Statera BioPharma to develop and commercialize STAT-201 for Crohn's disease; and Vici Heal...[Read more]
Industry
Biotechnology
IPO Date
2020-12-17
Stock Exchange
PNK
Ticker
COEP
According to Coeptis Therapeutics, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -0.51. This represents a change of -55.40% compared to the average of -1.14 of the last 4 quarters.
The mean historical PE Ratio of Coeptis Therapeutics, Inc. over the last ten years is -5977.83. The current -0.51 PE Ratio has changed -99.15% with respect to the historical average. Over the past ten years (40 quarters), COEP's PE Ratio was at its highest in in the March 2020 quarter at 13.34M. The PE Ratio was at its lowest in in the June 2020 quarter at -59296.88.
Average
-5977.83
Median
-0.74
Minimum
-47777.25
Maximum
0.01
Discovering the peaks and valleys of Coeptis Therapeutics, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 77.37%
Maximum Annual PE Ratio = 0.01
Minimum Annual Increase = -Infinity%
Minimum Annual PE Ratio = -47777.25
Year | PE Ratio | Change |
---|---|---|
2023 | -0.95 | 77.37% |
2022 | -0.53 | -96.23% |
2021 | -14.17 | -52.30% |
2020 | -29.72 | -99.94% |
2019 | -47777.25 | -Infinity% |
2018 | 0 | -100.00% |
2005 | -0.05 | -868.98% |
The current PE Ratio of Coeptis Therapeutics, Inc. (COEP) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-5.22
5-year avg
-9564.52
10-year avg
-5977.83
Coeptis Therapeutics, Inc.’s PE Ratio is less than SeaStar Medical Holding Corporation (-0.27), greater than Virios Therapeutics, Inc. (-0.76), less than ZyVersa Therapeutics, Inc. (-0.00), less than Sonnet BioTherapeutics Holdings, Inc. (-0.18), less than Revelation Biosciences, Inc. (-0.05), greater than Clearmind Medicine Inc. (-0.84), greater than Hillstream BioPharma, Inc. (-0.99), less than Magenta Therapeutics, Inc. (-0.15), less than Quoin Pharmaceuticals, Ltd. (-0.28), greater than Genelux Corporation (-2.98), less than Comera Life Sciences Holdings, Inc. (-0.00), greater than Dyadic International, Inc. (-8.11), less than Cingulate Inc. (-0.00), greater than Monopar Therapeutics Inc. (-0.59), greater than YS Biopharma Co., Ltd. (-0.80), less than Allarity Therapeutics, Inc. (-0.08), greater than Kiromic BioPharma, Inc. (-1.17), less than Aditxt, Inc. (-0.00), less than Palisade Bio, Inc. (-0.18), greater than Plus Therapeutics, Inc. (-0.66),
Company | PE Ratio | Market cap |
---|---|---|
-0.27 | $9.06M | |
-0.76 | $206.50K | |
-0.00 | $2.70M | |
-0.18 | $4.27M | |
-0.05 | $2.51M | |
-0.84 | $7.54M | |
-0.99 | $4.17M | |
-0.15 | $42.44M | |
-0.28 | $2.45M | |
-2.98 | $82.55M | |
-0.00 | $6.15K | |
-8.11 | $51.49M | |
-0.00 | $15.61M | |
-0.59 | $116.38M | |
-0.80 | $192.09M | |
-0.08 | $4.50M | |
-1.17 | $1.47M | |
-0.00 | $2.62M | |
-0.18 | $4.73M | |
-0.66 | $6.37M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Coeptis Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Coeptis Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Coeptis Therapeutics, Inc.'s PE Ratio?
How is the PE Ratio calculated for Coeptis Therapeutics, Inc. (COEP)?
What is the highest PE Ratio for Coeptis Therapeutics, Inc. (COEP)?
What is the 3-year average PE Ratio for Coeptis Therapeutics, Inc. (COEP)?
What is the 5-year average PE Ratio for Coeptis Therapeutics, Inc. (COEP)?
How does the current PE Ratio for Coeptis Therapeutics, Inc. (COEP) compare to its historical average?